RxDoctor Payments Data

Mayuri Bharathan

Medical · Berkley, MINPI 1487395455

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,145 of the $7,844 with a category attached, or 78.3%. 10 manufacturers reported payments, led by Gilead at 57.1% of the total. Reporting peaked in 2023 at $3,387 and has fallen 69.2% since, to $1,042 in 2025. Among medical clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,844in general payments, 2019–2025

Across 222 payments — averaging $35.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Viiv Healthcare Company$2K
  • Merck$392
  • Braeburn Inc.$197
  • Indivior Inc.$139
  • AbbVie$118
  • plus $118 from 4 others

What the payments were for

  • Consulting fees$1,57020%
  • Travel & lodging$1292%
  • Food & beverage$6,14578%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,844 in reported general payments places this provider in the 90th percentile of 755 medical providers in Michigan.

See all medical providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala36$148,123
DovatoDolutegravir Sodium/Lamivudine24$66,284
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl92$19,084
LinzessLinaclotide12$6,074
Advair HfaFluticasone Propion/Salmeterol12$4,303
Venlafaxine Hcl ErVenlafaxine Hcl16$1,010
Albuterol Sulfate HfaAlbuterol Sulfate25$778
Gabapentin72$489
Quetiapine Fumarate34$466
Tamsulosin Hcl23$433
Bupropion XlBupropion Hcl12$342
Cyclobenzaprine Hcl30$272
Omeprazole30$234
Atorvastatin Calcium37$228
Hydroxyzine Pamoate12$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$4,482$148,12336 claims
Viiv Healthcare CompanyDovato$2,398$66,28424 claims
AbbVieLinzess$118$6,07412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 755 medical providers in Michigan.

Other medical in Berkley

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →